LE-127/2, a new cannabigerol derivative mediated autophagy in different human melanoma cell lines

Abstract

melanoma, a rapidly increasing type of skin cancer arising from melanocytes, poses a significant global health threat due to its aggressive nature and high mortality rates. Compounds from Cannabis sativa have shown promise in inhibiting melanoma cell growth and inducing cell death. Non-psychoactive cannabinoids like cannabigerol (CBG) have been investigated for their anti-tumor effects, with some success. This study focused on a new CBG derivative, LE-127/2, comparing its effects on melanoma cell growth to the established drug vemurafenib. Additionally, the study explored how LE-127/2 influences autophagy-related proteins in melanoma cells, suggesting that LE-127/2-induced autophagy may inhibit cell proliferation and trigger cell death in melanoma cells.